XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Schedule of activity under the stock option plans
   2010 Plan   2017 Plan   Weighted
Average
Exercise
Price
   Aggregate
Intrinsic
Value(1)
 
Outstanding as of December 31, 2020   237,500    176,500   $6.38   $(180,038)
Grants   
    86,000   $9.78      
Terminations/forfeitures   (12,000)   (20,000)  $7.26      
Exercises   (7,000)   (18,000)  $7.08      
Outstanding as of December 31, 2021   218,500    224,500   $6.94   $468,425 
Grants   
    156,500   $8.14      
Terminations/forfeitures   (9,000)   (22,500)  $7.47      
Exercises   (5,000)   
   $6.13      
Outstanding as of September 30, 2022   204,500    358,500   $7.25   $127,538 
Vested as of September 30, 2022   174,500    98,500   $6.79   $188,040 
Vested and expected to vest as of September 30, 2022   204,500    358,500   $7.25   $127,538 
Reserved for future grants   
    273,500           

 

Schedule of additional information about the stock option plans
   Number of
Shares
   Weighted
Average
Fair Value at
Grant Date
   Weighted
Average
Exercise
Price
 
Non-vested stock options as of January 1, 2022   160,000   $3.36   $7.23 
Non-vested stock options as of September 30, 2022   290,000   $3.83   $7.69 
Stock options granted during the nine-month period ended September 30, 2022   156,500   $4.36   $8.14 
Stock options that vested during the nine-month period ended September 30, 2022   4,000   $3.44   $6.54 
Stock options that were forfeited during the nine-month period ended September 30, 2022   31,500   $4.10   $7.47 

 

Schedule of fair value stock option grant using black-scholes option pricing model with the weighted-average assumptions
  

During the Three-Month
Periods Ended
September 30,

  

During the Nine-Month
Periods Ended
September 30,

 
   2022   2021   2022   2021 
Risk-free interest rate   3.98%   0.79%   2.84%   0.85%
Dividend yield   0%   0%   0%   0%
Expected volatility   52%   54%   53%   54%
Expected life   6.6 years    6.5 years    6.5 years    5.0 years